Cantor Fitzgerald Comments on PRQR FY2025 Earnings

ProQR Therapeutics (NASDAQ:PRQR) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of ProQR Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim forecasts that the biopharmaceutical company will post earnings per share of ($0.36) for the year. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share.

Several other equities research analysts have also recently weighed in on the company. Chardan Capital reissued a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. JMP Securities reissued a “market outperform” rating and set a $8.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Oppenheimer assumed coverage on shares of ProQR Therapeutics in a research report on Friday, January 10th. They issued an “outperform” rating and a $15.00 price target on the stock. Raymond James raised shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price objective for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, ProQR Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $8.83.

ProQR Therapeutics Stock Down 2.7 %

Shares of NASDAQ:PRQR opened at $2.17 on Wednesday. The firm has a market cap of $177.25 million, a P/E ratio of -6.78 and a beta of 0.30. ProQR Therapeutics has a 12-month low of $1.61 and a 12-month high of $4.62. The business has a fifty day simple moving average of $2.99 and a 200 day simple moving average of $2.55.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01. ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. The firm had revenue of $4.22 million during the quarter, compared to the consensus estimate of $4.75 million.

Institutional Trading of ProQR Therapeutics

Hedge funds have recently modified their holdings of the stock. Ballentine Partners LLC bought a new position in ProQR Therapeutics during the fourth quarter worth $61,000. OneDigital Investment Advisors LLC raised its holdings in shares of ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 15,550 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 7,300 shares during the period. Finally, Privium Fund Management B.V. boosted its position in shares of ProQR Therapeutics by 0.9% during the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock worth $10,251,000 after purchasing an additional 51,663 shares in the last quarter. Institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).